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relationship between magnetic resonance imaging 
signal intensity and volume of extraocular muscles 
in thyroid-associated ophthalmopathy with 
methylprednisolone pulse therapy
Tomoaki higashiyama1
Yasuhiro nishida2
Masahito Ohji1
1Department of Ophthalmology, 
2Clinical Medical education Center, 
shiga University of Medical science, 
shiga, Japan
Purpose: To characterize the relationship between inflammation and swelling of extraocular 
muscles in thyroid-associated ophthalmopathy before and after methylprednisolone pulse 
therapy.
Methods: The signal intensities and volumes of the superior rectus (SR), inferior rectus (IR), 
lateral rectus (LR), medial rectus (MR), and superior oblique (SO) muscles were measured with 
magnetic resonance imaging in 25 eyes of 25 patients with thyroid-associated ophthalmopathy 
in the acute inflammatory phase before and after methylprednisolone pulse therapy. The signal 
intensity ratios (SIRs) of muscles and brain white matter were calculated.
Result: The mean SIRs before treatment were 2.28±0.74 in SR, 2.66±0.57 in IR, 2.03±0.42 
in LR, 2.45±0.49 in MR, and 1.98±0.48 in SO muscles. The mean SIRs after treatment were 
1.82±0.62, 1.84±0.52, 1.70±0.35, 1.95±0.46, and 1.60±0.36, respectively. The mean volumes 
(cm3) before treatment were 1.35±0.67 in SR, 1.21±0.39 in IR, 0.66±0.13 in LR, 0.94±0.31 in 
MR, and 0.58±0.14 in SO muscles. Those after treatment were 1.12±0.45, 0.91±0.31, 0.61±0.12, 
0.85±0.28, and 0.49±0.11, respectively. The SIRs showed significantly positive correlations 
with volumes both before and after treatment in SR muscles (before, r=0.77; after, r=0.69), IR 
muscles (before, r=0.65; after, r=0.60), MR muscles (before, r=0.69; after, r=0.73), and SO 
muscles (before, r=0.52; after, r=0.50) (P,0.01 for all correlations).
Conclusion: Swelling reflected the inflammation in extraocular muscles of thyroid-associated 
ophthalmopathy both before and after treatment.
Keywords: thyroid-associated ophthalmopathy, methylprednisolone pulse therapy, extraocular 
muscle, magnetic resonance imaging, signal intensity, volume
Introduction
Thyroid-associated ophthalmopathy (TAO) is an inflammatory autoimmune disorder 
of the orbit. The symptoms of TAO caused by inflammatory swelling of the orbital 
tissues involve ocular motility dysfunction, proptosis, periorbital swelling, chemosis, 
lid retraction, and optic neuropathy.1–4 Ocular motility dysfunction, which affects 
quality of life, is caused by the inflammatory swelling of the extraocular muscles.
Previous studies reported immunosuppressive therapy, such as corticosteroids and 
orbital radiotherapy, for patients with TAO in the acute active inflammatory phase.2,5–9 
The European Group on Graves’ Orbitopathy recommends methylprednisolone 
pulse therapy for moderate-to-severe active TAO.10 Previous studies reported the 
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effectiveness of this treatment for inflammation and swelling 
of extraocular muscles in TAO.11–17
The short-tau inversion-recovery (STIR) technique of 
magnetic resonance imaging (MRI) is useful for evalu-
ating inflammation in the extraocular muscles of TAO 
because the STIR images show high signal intensity in the 
edematous lesions caused by inflammation.15,16,18–23 We pre-
viously reported that signal intensities in the extraocular 
muscles of TAO after methylprednisolone pulse therapy 
were significantly lower than those before treatment,16 and 
the volumes in total extraocular muscles were improved after 
methylprednisolone pulse therapy.17
Although changes of inflammation and swelling in TAO 
have been reported, the relationships between inflammation 
and swelling of each extraocular muscle involved in TAO 
with methylprednisolone pulse therapy are unknown.15–17 
To characterize these relationships, we measured and corre-
lated the signal intensities and volumes of extraocular muscles 
before and after methylprednisolone pulse therapy.
Methods
subjects
Twenty-five eyes of 25 Japanese patients (18 female and 
seven male) with TAO in the acute inflammatory phase were 
included in this study at the Department of Ophthalmology, 
Shiga University of Medical Science Hospital, Japan, 
from April 2008 to April 2015. This retrospective study 
was approved by the Institutional Review Board of Shiga 
University of Medical Science and was conducted in 
accordance with the tenets of the Declaration of Helsinki. 
Written informed consent was obtained from each patient in 
the study. All patients suffered from diplopia due to ocular 
motility dysfunction. The diagnosis of TAO in the acute 
inflammatory phase was based on a high signal intensity of 
the extraocular muscles on STIR images, high levels of serum 
thyroid autoantibodies, presence of typical clinical signs of 
TAO, and a history of hyperthyroidism or hypothyroidism. 
Patients were excluded if they had orbital diseases, such as 
trauma, an inflammatory disease of unknown origin in the 
orbit, a high risk for methylprednisolone pulse therapy, or 
had previously undergone orbital radiotherapy or surgery 
for TAO. Clinical activity of TAO was determined for each 
patient before treatment according to the clinical activity 
score (CAS), as recommended by the European Group on 
Graves’ Orbitopathy (a maximal score of 7 points).10 The 
eye in which the mean signal intensity of five measured 
extraocular muscles was highest was selected as representa-
tive of the patient.
All patients were admitted to the Department of 
Medicine in our hospital and received methylprednisolone 
pulse therapy, which was administered at a daily dose of 
500 or 1,000 mg for three successive days. This treatment 
was repeated weekly three times for 3 weeks. In 19 cases 
(cases 6–25), the daily dose of methylprednisolone was 
decreased to 500 mg because the European Group on Graves’ 
Orbitopathy recommends that the total cumulative dose 
should be less than 8 g in one course of therapy to prevent 
acute liver damage.10 Instead, oral prednisolone was admin-
istered at a daily dose of 30 mg on four successive days as 
interpulse therapy. After three successive methylprednisolone 
pulse therapies, oral prednisolone therapy was administered 
at an initial daily dose of 30 or 40 mg/day and then gradually 
decreased while monitoring the activity of TAO.
Magnetic resonance image acquisition
The orbital MRI examinations were performed on a 3.0 Tesla 
MRI scanner (Achieva 3.0 T Quasar Dual; Royal Philips 
Electronics, Amsterdam, the Netherlands) with a standard 
head coil. The protocol of the examination consisted of the 
following sequence: STIR images (repetition time, 3,700 ms; 
echo time, 50 ms; inversion time, 200 ms; field of view, 
120 mm; matrix, 256×320; number of excitations, two; 
and slice thickness, 2.5 mm), and T2-weighted spin echo 
(repetition time, 3,000 ms; echo time, 85 ms; field of view, 
120 mm; matrix, 256×512; number of excitations, two; and 
slice thickness, 2.5 mm). The patients were instructed to gaze 
at the center during scanning. The MRI examinations were 
performed within 3 months before and after methylpredni-
solone pulse therapy.
signal intensity measurements
The coronal STIR and T2-weighted images of MRI were 
used to measure the signal intensities in the superior rectus 
(SR), inferior rectus (IR), lateral rectus (LR), medial rectus 
(MR), and superior oblique (SO) muscles. The outlines of 
the extraocular muscles were traced in T2-weighted images 
because the contrast of STIR images was low. The outlines 
were superimposed in the STIR images on the same slice 
level of the T2-weighted images, and signal intensities 
of muscles in the STIR images were measured. The SR 
muscle and the levator palpebrae muscle were traced together 
because it was difficult to separate them on the MRI images. 
The signal intensity of the inferior oblique muscle was not 
measured in this study because this muscle included only a 
few slices of the coronal MRI image and it was difficult to 
calculate a representative signal intensity ratio (SIR) value. 
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The signal intensities were measured by one of two 
ophthalmologists (TH or YN) who were experienced in TAO 
and orbital MRI.
To standardize the signal intensities of the extraocular 
muscles, we measured the signal intensity of the brain white 
matter in the coronal STIR images as the standard tissue and 
calculated the SIR of the signal intensity in the extraocular 
muscle to that of the white matter from the same slice 
(Figure 1). The highest value among the mean SIRs of three 
consecutive slices in each subject was the representative 
value of the SIR in the muscle.
Volume measurements
The cross-sectional areas of the five extraocular muscles 
(ie, SR, IR, LR, MR, and SO muscles) were measured by 
tracing outlines of each tissue on T2-weighted images with 
Image J software (National Institutes of Health, http://rsbweb.
nih.gov/ij/index.html) (Figure 2).24 The cross-sectional 
areas for the SR and IR muscles were measured on sagittal 
images, and for MR, LR, and SO muscles on axial images. 
The SR and the levator palpebrae muscles were traced 
together, the same as the measurement of signal intensity. 
The volume of each tissue was calculated by multiplying 
the sum of the cross-sectional areas by the slice increment 
(slice thickness =2.5 mm) in the same manner as previous 
studies.17,25,26 The volumes were measured by one ophthal-
mologist (TH).
assessment of Cas
The CAS was measured based on the following clinical 
findings: spontaneous retrobulbar pain, pain on attempted 
up or down gaze, redness of the eyelids, redness of the 
conjunctiva, swelling of the eyelids, and inflammation of 
the caruncle and/or plica and conjunctival edema.10 CAS 
was the sum of all items, and the maximal score was 7 points. 
The CAS values before and after treatment were determined 
by the same ophthalmologist (TH or YN). We analyzed 
the correlations of CAS values with the mean SIRs of five 
measured extraocular muscles or the total volume of five 
measured extraocular muscles to evaluate the correlation of 
the activity of the whole orbital inflammation and that of the 
muscle inflammation during TAO.
statistical analysis
The Shapiro–Wilk test was used to test the normality 
of the numerical variables. A paired t-test was used to 
compare the SIRs, the volumes, and CAS values before 
and after treatment. An unpaired t-test was used to compare 
the SIRs and volumes between the two thyroid function 
groups. Pearson product-moment correlation coefficient 
or Spearman’s rank correlation coefficient was used to 
analyze the correlations between the SIRs and the volumes 
/5
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62
Figure 1 Measurement of signal intensities of extraocular muscles using a short-tau 
inversion-recovery image.
Notes: The signal intensities of each muscle and the brain were measured as shown 
in the right orbit and brain. To standardize the signal intensity of each muscle, the 
ratio of the signal intensity in each muscle to that in white matter of the same slice 
was calculated.
Abbreviations: ir, inferior rectus; lr, lateral rectus; Mr, medial rectus; 
sO, superior oblique; sr, superior rectus; WM, white matter.
65
,5
/5 05
62
$ % &
Figure 2 Measurement of the cross-sectional areas of extraocular muscles on T2-weighted images.
Notes: (A) sagittal slice showing the cross-sectional areas of the sr and ir muscles in the right orbit. (B) axial slice showing the cross-sectional areas of the lr and Mr 
muscles in the right orbit. (C) axial slice showing the cross-sectional areas of the sO muscle in the right orbit.
Abbreviations: ir, inferior rectus; lr, lateral rectus; Mr, medial rectus; sO, superior oblique; sr, superior rectus.
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before and after treatment, those of CAS values with SIRs 
or volumes, and those of the duration before MRI with SIRs 
or volumes. PASW Statistics 18 software (IBM, Armonk, 
NY, USA) was used for all analyses. Data were expressed 
as the mean ± standard deviation. P,0.05 was considered 
statistically significant.
Results
Characteristics of patients
The characteristics of the patients before treatment are 
shown in Table 1. The mean ± standard deviation of 
patient age was 56.0±9.6 years (range, 35–74 years). The 
mean duration between the onset of diplopia and the start 
of treatment was 3.6±2.1 months (range, 1–8 months). 
Twenty-four patients had Graves’ disease and one patient 
had Hashimoto’s thyroiditis.
sirs
The mean SIRs before treatment were 2.28±0.74 in the 
SR, 2.66±0.57 in the IR, 2.03±0.42 in the LR, 2.45±0.49 in 
the MR, and 1.98±0.48 in the SO muscles. Those after the 
treatment were 1.82±0.62, 1.84±0.52, 1.70±0.35, 1.95±0.46, 
and 1.60±0.36, respectively. The mean SIRs after treatment 
were significantly decreased compared with those before 
treatment in all muscles (P,0.001) (Figure 3).
Volumes
The mean volumes before treatment were 1.35±0.67 cm3 
in the SR, 1.21±0.39 cm3 in the IR, 0.66±0.13 cm3 in 
the LR, 0.94±0.31 cm3 in the MR, and 0.58±0.14 cm3 in the 
Table 1 Characteristics of patients with TaO
Case Age Sex Duration of 
notice of diplopia 
before treatment 
(months)
Daily dose of 
methylprednisolone 
pulse therapy (mg)
Daily dose of oral 
prednisolone 
interpulse 
therapy (mg)
Daily dose of oral 
prednisolone after 
methylprednisolone 
pulse therapy (mg)
Thyroid 
function 
before 
treatment
Thyroid 
function 
after 
treatment
1 47 M 2 1,000 none 30 e e
2 48 M 2 1,000 none 30 e e
3 63 F 2 1,000 none 30 e e
4 57 F 6 1,000 none 40 e e
5 67 M 1 1,000 none 30 e e
6 60 F 2 500 30 30 e e
7 41 F 2 500 30 30 e e
8 54 F 8 500 30 30 e e
9 49 F 1 500 30 30 e e
10 59 F 2 500 30 30 h e
11 67 F 4 500 30 30 e e
12 58 M 2 500 30 30 e e
13 35 M 3 500 30 30 e e
14 48 F 5 500 30 30 h e
15 74 F 2 500 30 30 e e
16 50 F 3 500 30 30 h e
17 63 M 7 500 30 30 h e
18 63 F 2 500 30 30 e e
19 60 F 5 500 30 30 e e
20 63 F 7 500 30 30 h e
21 57 F 3 500 30 30 e e
22 65 F 2 500 30 30 e e
23 40 M 6 500 30 30 e e
24 50 F 7 500 30 30 e e
25 63 F 3 500 30 30 h e
Abbreviations: e, euthyroid; F, female; h, hyperthyroid; M, male; TaO, thyroid-associated ophthalmopathy.
 65 ,5 /5 05 62
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Figure 3 The signal intensity ratios (sirs) of the extraocular muscles before and 
after treatment (left plots, before; right plots, after).
Note: The mean SIRs after treatment were significantly lower (P,0.01) in all 
measured muscles than those before treatment.
Abbreviations: ir, inferior rectus; lr, lateral rectus; Mr, medial rectus; sO, 
superior oblique; sr, superior rectus.
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SO muscles. Those after treatment were 1.12±0.45, 0.91±0.31, 
0.61±0.12, 0.85±0.28 , and 0.49±0.11 cm3, respectively. The 
mean volumes after treatment were significantly decreased 
compared with those before treatment in all muscles (SR, MR, 
P,0.01; IR, SO, P,0.001; LR, P=0.02) (Figure 4).
Correlations of sirs and volumes
The SIRs showed significant positive correlations with 
the volumes in the SR, IR, MR, and SO muscles both 
before and after treatment (before: SR, r=0.77, P,0.001; 
IR, r=0.65, P,0.001; MR, r=0.69, P,0.001; and SO, 
r=0.56, P=0.003; after: SR, r=0.69, P,0.001; IR, r=0.60, 
P=0.001; MR, r=0.73, P,0.001; SO, and r=0.51, P=0.01) 
(Figures 5 and 6). However, the volumes remained large, 
although signal intensities were low after treatment in some 
extraocular muscles.
Cas
The mean CAS was 2.5±1.5 before treatment and 1.4±1.4 
after treatment. The mean CAS was significantly decreased 
after treatment (P,0.001). The CAS values showed sig-
nificant positive correlations with the mean SIR of the five 
extraocular muscles both before and after treatment (before; 
r=0.40, P=0.046; after; r=0.41, P=0.04; Figure 7). The CAS 
values showed significant positive correlations with the total 
volume of the five measured extraocular muscles both before 
and after treatment (before; r=0.49, P=0.01; after; r=0.44, 
P=0.03; Figure 8).
Correlation of durations before Mri with 
sirs or volumes
Regarding the duration between the diagnosis of Graves’ 
disease or Hashimoto’s thyroiditis and the MRI examination 
before treatment, the mean was 47.4±79.6 months (range, 
0–317 months). The durations showed significant positive 
correlations with the SIRs and the volumes in the IR before 
treatment (SIRs, r=0.51, P=0.009; volumes, r=0.51, P=0.009) 
(Figure 9). In the mean duration between the diagnosis of 
TAO and the MRI examination before treatment, the mean 
was 1.9±3.8 months (range, 0–13 months). The durations 
were not significantly correlated with the SIRs and volumes 
of the extraocular muscles.
Comparison of thyroid function between 
the two groups
The thyroid function before methylprednisolone pulse 
therapy was hyperthyroid in six patients with Graves’ disease 
(hyperthyroid group) and euthyroid in the other 19 patients 
(euthyroid group). The mean duration between the diagnosis 
of Graves’ disease or Hashimoto’s thyroiditis and the MRI 
before treatment was 16.2±39.6 months (range, 0–97 months) 
in the hyperthyroid group and 57.2±87.1 months (range, 
1–317 months) in the euthyroid group. Five patients in the 
hyperthyroid group were diagnosed with Graves’ disease and 
TAO at the same time. The thyroid function after treatment 
was euthyroid in all patients.
The mean SIRs in hyperthyroid group before treat-
ment were 1.93 in the SR, 2.47 in the IR, 1.91 in the LR, 
2.10 in the MR, and 1.74 in the SO muscles. Those in the 
 65 ,5 /5 05 62
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Figure 4 The volumes of the extraocular muscles before and after treatment (left 
plots, before; right plots, after).
Note: The mean volumes after treatment were significantly lower in all measured 
muscles than those before treatment (sr, Mr: P,0.01; ir, sO: P,0.001; and 
lr: P=0.02).
Abbreviations: ir, inferior rectus; lr, lateral rectus; Mr, medial rectus; 
sO, superior oblique; sr, superior rectus.



6,5
65
9ROX
PH
FP
 



6,5
,5
 6,5
05

 6,5
62

Figure 5 Correlation between the signal intensity ratios (sirs) and volumes before treatment.
Note: The SIRs showed significant positive correlations with the volumes in SR, IR, MR, and SO muscles before treatment (before: SR, r=0.77, P,0.001; ir, r=0.65, P,0.001; 
Mr, r=0.69, P,0.001; and sO, r=0.56, P=0.003).
Abbreviations: ir, inferior rectus; Mr, medial rectus; sO, superior oblique; sr, superior rectus.
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Figure 6 Correlation between the signal intensity ratios (sirs) and volumes after treatment.
Note: The SIRs showed significant positive correlations with the volumes in SR, IR, MR, and SO muscles after treatment (SR, r=0.69, P,0.001; ir, r=0.60, P=0.001; 
Mr, r=0.73, P,0.001; and sO, r=0.51, P=0.01).
Abbreviations: ir, inferior rectus; Mr, medial rectus; sO, superior oblique; sr, superior rectus.
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Figure 7 Correlation between the clinical activity scores (Cass) and signal intensity ratios (sirs) before and after treatment.
Notes: The CASs showed significant positive correlations with the mean SIRs of the five extraocular muscles both before (A) and after (B) treatment (before; r=0.40, 
P=0.046; after; r=0.41, P=0.04).
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Figure 8 Correlation between the clinical activity scores (Cass) and volumes before and after treatment.
Notes: The CASs showed significant positive correlations with the total volume of the five measured extraocular muscles both before (A) and after (B) treatment (before; 
r=0.49, P=0.01; after; r=0.44, P=0.03).
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euthyroid group before treatment were 2.39, 2.72, 2.07, 
2.56, and 2.06, respectively. The mean SIR in the MR of 
the hyperthyroid group was significantly smaller than that 
of the euthyroid group (P=0.04). The mean changes of 
SIR before and after treatment in the hyperthyroid group 
were −0.28, −0.88, −0.32, −0.45, and −0.34 and those in the 
euthyroid group were −0.53, −0.80, −0.33, −0.51, and −0.39, 
respectively. There was no significant difference between the 
two groups in the mean changes of SIR.
The mean volumes in the hyperthyroid group before treat-
ment were 1.06 cm3 in the SR, 0.93 cm3 in the IR, 0.60 cm3 in 
the LR, 0.73 cm3 in the MR, and 0.51 cm3 in the SO muscles. 
Those after treatment were 1.44, 1.30, 0.68, 1.01, and 
0.61 cm3, respectively. The mean volumes in the IR and MR 
of the hyperthyroid group were significantly smaller than those 
of the euthyroid group (IR, P=0.006; MR, P=0.01). The mean 
changes of volume before and after treatment in the hyperthyroid 
group were −0.11, −0.20, −0.05, −0.06, and −0.05 cm3 and 
those in the euthyroid group were −0.27, −0.33, −0.05, −0.10, 
and −0.11 cm3, respectively. There was no significant dif-
ference between the two groups in the mean changes of 
volume.
Discussion
The present study demonstrated that the SIRs show significant 
positive correlations with the volumes in SR, IR, MR, and 
SO muscles, both before and after treatment. Inflammation 
causes the swelling in the extraocular muscles of TAO. 
A previous study reported that the SIRs of the most inflamed 
extraocular muscles in STIR images showed significant 
positive correlations with total muscle volumes before 
treatment of TAO.27 In the present study, we showed that 
the swelling reflected the inflammation in each extraocular 
muscle of TAO both before and after treatment. Therefore, 
a decrease in swelling requires adequate anti-inflammatory 
treatment of the extraocular muscles.
The CAS values showed significant positive correlations 
with not only the mean SIR but also with the total volume 
of the five extraocular muscles before and after treatment. 
A previous study reported that the SIRs of the extraocular 
muscles in TAO showed significant positive correlations with 
CAS values.23 Another study also reported that the SIRs of 
the extraocular muscles in TAO showed significant positive 
correlations with the Morits score, which is the basis for 
CAS.22 In the present report, we show that not only inflam-
mation but also swelling of the extraocular muscles could 
be correlated with the CAS values in TAO.
The SIRs did not show statistically significant cor-
relations with the volume in LR muscles both before and 
after treatment because the involvement of LR muscles 
was low. Wiersinga et al28 reported that orbital computed 
tomography in 80 patients with TAO showed enlargement 
of the IR muscle in 60%, MR muscle in 50%, SR muscle 
in 40%, and LR muscle in 22% of patients. Many previous 
studies have reported similar results.29,30
In the present study, the volumes of the extraocular 
muscles were not standardized as they were in previous 
studies.31–33 However, the results were not affected because 
differences according to sex or age were not found in the 
volumes of the extraocular muscles.34,35
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Figure 9 Correlation between the duration before magnetic resonance imaging (Mri) and the signal intensity ratios (sirs) or volumes in the inferior rectus (ir) before 
treatment.
Notes: In the duration between diagnosis of Graves’ disease or Hashimoto’s thyroiditis and the MRI examination before treatment, the durations showed significant positive 
correlations with the sirs (A) and volumes (B) in the ir before treatment (sirs, r=0.51, P=0.009; volumes, r=0.51, P=0.009).
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The mean SIR in the MR and the mean volumes in the IR 
and MR of the hyperthyroid group were significantly smaller 
than those of the euthyroid group. Dysthyroidism had been 
associated with worsening of TAO in a previous report.36 
However, our results showed that SIR and volume in the 
hyperthyroid group were worse than those in the euthyroid 
group. We assume the reason was that five patients in the 
hyperthyroid group were recent cases who were diagnosed 
with Graves’ disease and TAO at the same time.
There are some limitations associated with this study. 
First, the mean CAS of patients in this study was low. The 
CAS tends to be low in Japanese TAO patients who require 
treatment.37,38 The CAS of some patients was low in this 
study when the diagnosis of TAO in the acute inflammatory 
phase was confirmed, based on high signal intensity of the 
extraocular muscles in the STIR images, high levels of serum 
thyroid autoantibodies, and a history of hyperthyroidism or 
hypothyroidism. Second, the follow-up period to evaluate 
the changes of SIRs and volumes with treatment was within 
3 months after methylprednisolone pulse therapy. An assess-
ment of long-term changes is therefore needed for a better 
evaluation. However, TAO may naturally improve over 
time.39 Natural improvement had little effect on the results 
of this study, because the follow-up period after treatment 
was short. Third, the volumes remained large although signal 
intensities were low after treatment in some extraocular 
muscles. Fibrosis of extraocular muscles might therefore 
appear. Fourth, the patients who underwent orbital radio-
therapy or were treated with other drugs were not enrolled 
in the current study. Many previous studies have reported 
the efficacies of treatments for TAO.40,41
In conclusion, SIRs statistically showed significant posi-
tive correlations with volumes both before and after treatment. 
The swelling reflected the inflammation in each extraocu-
lar muscle of TAO both before and after treatment, and a 
decrease in swelling required adequate anti-inflammatory 
treatment of the extraocular muscles.
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